Thursday, 16 Aug 2018

You are here

The RheumNow Week in Review – FDA Showdown for Baricitinib (4.27.18)

Dr. Jack Cush reviews the news and FDA proceedings from the past week on RheumNow.com.

  1. UCSF study of 807 lupus pts shows that poverty is associated with a 2 fold increased risk of mortality in SLE pts, does so by increasing the extent of damage accumulation. Poor who died lived 13.9 fewer years. https://t.co/kGEnsuP2il
  2. A large CV prevention trial found 722 new gout cases among 12,866 men (age 35–57). Chronic kidney dz assoc w/ a 61% incr risk of gout (HR 1.61), increased w/ proteinuria & hematuria, but not by serum urate https://t.co/DOUBaACaM6
  3. Among 2619 RA patients, use of hydroxychloroquine (n 1212) was associated with a lower risk of CKD (10.3 vs 13.8 per 1000PY); thus HCQ assoc w/ a lower risk of incident CKD (HZ 0.64; 95% confidence interval, 0.45 to 0.90; P=0.01) & was dose dependent https://t.co/MaTsZEDBKG
  4. Study of 537 GCA pts undergoing temporal artery bx shows the value of CBC elements in predicting a +Bx: Thrombocytosis (OR 4.44), NLR (OR 1.81), PLR (OR 3.25), CRP (OR 3.00), ESR (OR 3.62), increased age (OR 1.03) https://t.co/3XvzBR5cEh   
  5. FDA Arthritis advisory panel voting in progress. Early votes unanimously in favor of baricitinib efficacy at 4 mg (15-0) or 2mg(14-1 unfavorably)
  6. FDA Arthritis advisory panel voting on baricitinib safety was 9-6 in favor of 2mg and was 11-4 against the safety of 4 mg 
  7. FDA Arthritis panel on Baricitinib approval in RA votes 10-5 in favor of 2 mg dose but voted 10-5 Against baricitinib 4 mg dose. Concerns about safety of 4 mg dose, esp VTE, thrombophilia 
  8. FDA Arthritis Panel Split on the Efficacy and Safety of Baricitinib in RA  
Disclosures: 
The author has an ownership interest in this subject

Add new comment

More Like This

U.S. News 2018-19 Rheumatology Rankings

The Annual U.S. News and World Report Rankings of Hospitals has listed the top contenders in the field of rheumatology. The U.S. News Review rates hospitals nationwide in 16 specialties – including rheumatology. Of the 4,500 hospitals covered by U.S. News that were analyzed, 158 were classified nationally in at least one specialty area.

The RheumNow Week in Review – No Good Gout (8.10.18)

Dr. Jack Cush reviews the news and latest journal articles from the past week on RheumNow.com. Info on Surgery and Hip Fractures, Gout drugs abandoned, Allopurinol escalation, hydroxychloroquine drug levels, how to treat scleroderma in India and exactly who gets back pain.

The RheumNow Week in Review – Handshakes or Hugs (8.3.18)

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com, including new treatments for LTBI, gout consequences, RA and offspring risk, PsA risk, and the opioid epidemic effects.

The RheumNow Week in Review – Lupus in the News (7.27.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

The RheumNow Week in Review – Cocoon Therapy? (7.20.18)

Dr. Jack Cush reviews highlights from the news and social media on RheumNow.com in the past week.